Compare AbbVie Inc (ABBV) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? AbbVie Inc trades at $248.68 (market cap $438.19B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.53. The key difference: AbbVie Inc pays a 2.79% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | HYG | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Fixed Income |
52-Week High | $263.58 | $81.32 |
52-Week Low | $197.38 | $78.72 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
HYG trades at $79.61, up 0.19% on the day, with a bullish technical signal driven by oscillators despite bearish moving averages. Recent dividends include $0.41 paid in June 2026. News highlights bond market volatility amid oil price swings and inflation data anticipation, with HYG noted for its high-yield corporate bond exposure and liquidity as the largest junk bond ETF.
Outlook hinges on interest rate trends and economic stability, offering income through dividends but facing risks from rising yields and credit spreads. Investors should weigh HYG's role in diversified portfolios against potential downside from macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
